LifeMD Reports Fourth Quarter and Full Year 2021 Results

Rhea-AI Summary

LifeMD, Inc. (NASDAQ: LFMD) reported a 149% increase in FY2021 revenue, totaling $92.9 million, with fourth quarter revenue reaching $27.4 million, up 113%. The fourth quarter Adjusted EPS improved 19% sequentially to $(0.29). The company achieved record gross margins of 81% and improved cash flow by 21% sequentially. With over $41 million in cash and no debt, FY2022 revenue guidance is between $142 million and $148 million, aiming for Adjusted EBITDA profitability by Q4 2022.

Positive

• FY2021 revenue increased 149% to $92.9 million.
• Fourth quarter revenue reached $27.4 million, a 113% year-over-year growth.
• Achieved record gross margins of 81%, up from 76% year-over-year.
• 93% of revenue now generated from subscriptions, an increase from 82%.
• Cash improved to $41.3 million with no debt.

Negative

• Adjusted EPS of $(0.29) remains in the negative.
• FY2021 net loss attributable to common stockholders was $61.8 million.
• Operating expenses rose to $129.2 million, up from $86.3 million in the prior year.

• FY2021 consolidated revenue of $92.9 million up 149% from the same year ago period; fourth quarter revenue of $27.4 million
• Fourth quarter Adjusted EPS of $(0.29), 19% sequential improvement versus the prior quarter
• Continued progress in reducing cash burn with a 21% sequential improvement in fourth quarter Operating Cash Flow versus prior quarter
• Record liquidity with over $41 million of cash as of year-end 2021 and no debt
• FY2022 revenue guidance of between $142 and $148 million; Company on track to achieve Adjusted EBITDA profitability by fourth quarter 2022
  

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and year ended December 31, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, March 7, 2022, at 4:30 p.m. Eastern time to discuss the results.

Q4 and FY2021 Financial Highlights

• Record fourth quarter revenue of $27.4 million, up 113%
• FY2021 consolidated revenue of $92.9 million, up 149%
• Record FY2021 Gross Margins of 81%, up from 76% in the same year-ago period
• 93% of revenue generated by subscriptions, up from 82%
• Gross profit for the fourth quarter totaled $21.8 million, up 144%
• $41.3 million of cash as of December 31, 2021 and no debt
• Adjusted EPS $(0.29) for the fourth quarter, a 19% sequential improvement versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below)
• Fourth quarter Operating Cash Flow of ($5.8) million, a 21% sequential improvement versus the prior quarter

Q4 and Recent Operational Highlights

• Continued leverage of Selling and Marketing expenses despite market headwinds, with fourth quarter expenses as a percentage of revenue reducing to 77%, a 400 basis point improvement versus the prior quarter and a 5,800 basis point improvement versus the same year-ago period.
• Completed a public offering of 3,833,334 shares of its common stock and 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock raising approximately $55 million in net proceeds.
• Total patients and customers served nationwide surpassed 493,000 as of the quarter ending 12/31/2021, up from 250,000 as of 12/31/2020
• Telehealth orders increased 107% to approximately 242,000
• Announced appointment of seasoned Technology leader, Dennis Wijnker, as Chief Technology Officer and transition of Stefan Galluppi to Chief Innovation and Marketing Officer
  

Subsequent Events

• Announced full-scale national launch of the Company’s virtual primary care platform in February 2022 following a successful beta launch last November
• On January 18, 2022, the Company closed the acquisition of Cleared, a leading allergy, asthma and immunology telehealth platform. The Cleared platform offerings include prescription drug, FDA approved over-the-counter (OTC) treatments, diagnostics and a growing pipeline of pharmaceutical and biotech customer partners.

Key Performance Metrics

($ in 000s)		Three Months Ended December 31							Y-o-Y
Key Performance Metrics			2021			2020			% Growth
Revenue
Telehealth		$	20,573		$	10,297			100	%
WorkSimpli		$	6,844		$	2,596			164	%
Total Revenue		$	27,417		$	12,894			113	%
Subscription Revenue as % of Total			93	%		82	%		13	%
Telehealth Volume
Total Telehealth Orders			241,881			116,674			107	%
WorkSimpli
Active Subscribers			102,023			57,271			78	%

Management Commentary
“2021 was an extraordinary year for us, with record growth in sales of our products and services driving revenues to increase by 149% versus 2020. Equally as important, we began to demonstrate significant progress this year in driving meaningful improvements in reducing LifeMD’s cash burn on our way to achieving Adjusted EBITDA profitability by the fourth quarter of 2022 and further diversifying our telehealth platform,” said Justin Schreiber, CEO of LifeMD. “Following quarter end, we announced two transformational initiatives for the Company, including the acquisition of Cleared, a leading telehealth platform for allergy, asthma and immunology and the nationwide launch of our Virtual Primary Care platform which we demonstrated at our recent February 22^nd Analyst & Investor Day. The combination of these new business lines with our already successful platform brands and near-term pathway to profitability positions us uniquely well to continue our ascent as a leader in telehealth.”

LifeMD CFO Marc Benathen, commented: “During the fourth quarter we not only successfully capitalized the Company on a long-term basis, but continued to demonstrate our commitment to aggressively growing LifeMD with continued sequential improvement in quarterly profitability. We remain on track to achieve our stated goal of Adjusted EBITDA profitability by the fourth quarter of 2022, while at the same time investing in the growth of our Company.”

FY2021 Financial Summary

• Revenue for the year ended December 31, 2021 increased 149% to a record $92.9 million from $37.3 million in 2020. The increase in revenues was attributable to both the increase in telehealth revenue of 123% and an increase in WorkSimpli revenue of 267%.
  
  
• Gross profit increased by approximately 163% to $74.9 million, compared to $28.4 million in the prior year. Gross margin was 81% as compared to 76% in the prior year.
  
  
• Operating expenses in 2021 were $129.2 million, up from $86.3 million in the prior year. The increase was primarily due to increases in selling and marketing expenses of $43.5 million, customer service expenses of $2.1 million and other operating expenses of $2.4 million. General and Administrative expenses decreased $5.4 million during the year. General and Administrative expenses included $12.1 million of non-cash stock-based compensation expense.
  
  
• Net loss attributable to common stockholders for 2021 was $61.8 million or $(2.29) per share, as compared to a net loss attributable to common stockholders of $63.4 million or $(4.44) per share in the prior year.
  
  
• Excluding $12.1 million related to stock-based compensation expense, $6.1 million related to debt discounts/ extinguishments, $1.8 million of financing transaction expense, $0.9 million of depreciation and amortization expense, $0.9 million in preferred stock dividends and an income tax provision of $8 thousand, adjusted EPS, a non-GAAP measure, totaled a loss of $(1.48) per share as compared to a loss of $(1.74) in the same year-ago period (see definition of this non-GAAP financial measure and reconciliation to GAAP, below).
  
  
• Adjusted EBITDA, a non-GAAP financial measure, totaled a loss of $38.3 million, compared to an adjusted EBITDA loss of $14.9 million in the same year-ago period (see definition of this non-GAAP financial measure and reconciliation to GAAP, below).
  
  
• Cash totaled $41.3 million as of December 31, 2021.
  

Financial Guidance
For the First Quarter 2022, the Company expects:

• Revenue to total between $30 million and $32 million
• Adjusted EBITDA between $(6) million and $(7) million

For the Full Year 2022, the Company expects:

• Revenue to total between $142 million and $148 million
• Adjusted EBITDA between $(14) million and $(20) million

The Company remains on track to achieve Adjusted EBITDA profitability by the fourth quarter of 2022.

Conference Call
LifeMD’s management will host a conference call today, March 7, 2022 at 4:30 pm ET (1:30 pm PT) to discuss the company’s financial results and outlook, followed by a question-and-answer period. Details for the call are as follows:

Toll-free dial-in number:	1-877-705-6003
International dial-in number:	1-201-493-6725
Conference ID:	13727334
Webcast:	Click here

The conference call will be webcast live and available for replay via a link provided in the Investors section of the Company’s website at lifemd.com. Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Listeners are encouraged to review the Company's periodic reports filed with the U.S. Securities and Exchange Commission, including the discussion of risk factors, historical results of operations and financial condition as provided in these reports.

About LifeMD
LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.

Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Company Contact
LifeMD, Inc.
Marc Benathen, CFO
marc@lifemd.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com

Media Contact
Eric Herman
Kivvit
eherman@kivvit.com

Tables to Follow

LIFEMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
	December 31, 2021				December 31, 2020
ASSETS
Current Assets
Cash	$	41,328,039			$	9,179,075
Accounts receivable, net		980,055				997,757
Product deposit		203,556				816,765
Inventory, net		1,616,600				1,264,258
Other current assets		793,190				154,876
Total Current Assets		44,921,440				12,412,731
Non-current Assets
Equipment, net		233,805				-
Right of use asset, net		1,752,448				274,437
Capitalized software, net		2,995,789				375,983
Intangible assets, net		19,761				339,840
Total Non-current Assets		5,001,803				990,260
Total Assets	$	49,923,243			$	13,402,991
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses	$	20,654,819			$	12,143,420
Notes payable, net		63,400				779,132
Current operating lease liabilities		607,490				93,001
Deferred revenue		1,499,880				916,880
Total Current Liabilities		22,825,589				13,932,433
Long-term Liabilities
Noncurrent operating lease liabilities		1,178,544				192,322
Contingent consideration on purchase of WorkSimpli		100,000				100,000
Total Liabilities		24,104,133				14,224,755
Commitments and Contingencies
Mezzanine Equity
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized
Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, 3,500 and 3,500 shares issued and outstanding, liquidation value approximately, $1,175 and $1,045 per share as of December 31, 2021 and 2020, respectively		4,110,822				3,655,822
Stockholders’ Equity (Deficit)
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 and zero shares issued, 1,400,000 and zero shares issued and outstanding, liquidation value approximately $25.62 and $0 per share as of December 31, 2021 and 2020, respectively		140				-
Common Stock, $0.01 par value; 100,000,000 shares authorized, 30,704,434 and 23,433,663 shares issued, 30,601,394 and 23,330,623 outstanding as of December 31, 2021 and 2020, respectively		307,045				234,337
Additional paid-in capital		164,517,634				77,779,370
Accumulated deficit		(141,921,085	)			(80,151,905	)
Treasury stock, 103,040 and 103,040 shares, at cost		(163,701	)			(163,701	)
Total LifeMD, Inc. Stockholders’ Equity (Deficit)		22,740,033				(2,301,899	)
Non-controlling interest		(1,031,745	)			(2,175,687	)
Total Stockholders’ Equity (Deficit)		21,708,288				(4,477,586	)
Total Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit)	$	49,923,243			$	13,402,991

LIFEMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
	Fourth Quarter Ended December 31,								Year Ended December 31,
	2021				2020				2021				2020
Revenues
Telehealth revenue, net	$	20,573,309			$	10,297,413			$	68,197,128			$	30,561,163
WorkSimpli revenue, net		6,843,577				2,596,139				24,678,678				6,732,747
Total revenues, net		27,416,884				12,893,552				92,875,806				37,293,910
Cost of telehealth revenue		5,436,214				3,854,347				17,549,550				8,572,490
Cost of WorkSimpli revenue		131,416				84,455				445,844				288,696
Total cost of revenues		5,567,630				3,938,802				17,995,394				8,861,186
Gross profit		21,849,254				8,954,750				74,880,412				28,432,724
Expenses
Selling and marketing expenses		21,169,141				17,384,395				82,541,956				39,053,441
General and administrative expenses		11,375,433				23,090,902				39,569,738				44,958,999
Other operating expenses		1,061,502				421,716				3,452,196				1,076,663
Customer service expenses		1,564,439				227,870				2,838,831				716,325
Development costs		343,416				157,936				778,772				446,749
Total expenses		35,513,931				41,282,819				129,181,493				86,252,177
Operating loss		(13,664,677	)			(32,328,069	)			(54,301,081	)			(57,819,453	)
Interest expense, net		(153,566	)			(354,526	)			(3,019,716	)			(1,667,536	)
Loss on debt extinguishment		(4,180,473	)			(914,862	)			(3,995,559	)			(914,862	)
Net loss before provision for income taxes		(17,998,716	)			(33,597,457	)			(61,316,356	)			(60,401,851	)
Provision for income taxes		(7,700	)			(122,500	)			(7,700	)			(122,500	)
Net loss		(18,006,416	)			(33,719,957	)			(61,324,056	)		-	(60,524,351	)
Net income (loss) attributable to noncontrolling interests		104,830				(1,469,228	)			(426,352	)			(1,877,408	)
Net loss attributable to LifeMD, Inc.	$	(18,111,246	)		$	(32,250,729	)		$	(60,897,704	)		$	(58,646,943	)
Preferred dividends		(871,476	)			-				(871,476	)			-
Deemed distribution to holders of common and Series B Preferred stock		-				-				-				(4,716,021	)
Net loss attributable to LifeMD, Inc. common stockholders	$	(18,982,722	)		$	(32,250,729	)		$	(61,769,180	)		$	(63,362,964	)
Basic loss per share attributable to LifeMD, Inc. common stockholders	$	(0.62	)		$	(2.56	)		$	(2.29	)		$	(4.44	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders	$	(0.62	)		$	(2.56	)		$	(2.29	)		$	(4.44	)
Weighted average number of common shares outstanding:
Basic		30,572,003				12,581,401				27,007,961				14,275,153
Diluted		30,572,003				12,581,401				27,007,961				14,275,153

LIFEMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
		Fourth Quarter Ended December 31,										Year Ended December 31,
		2021					2020					2021					2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(18,006,416	)			$	(33,719,957	)			$	(61,324,056	)			$	(60,524,351	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount			-					-					2,090,236					817,118
Amortization of capitalized software			334,961					26,152					512,887					62,153
Amortization of intangibles			1,853					83,903					342,310					335,612
Write-down of inventory			-					-					57,481					-
Depreciation of fixed assets			10,695					-					13,560					-
Acceleration of debt discount			-					-					-					500,145
Loss on debt extinguishment, net			4,180,473					914,862					3,995,559					914,862
Operating lease payments			17,018					818					22,700					4,533
Liability to issue shares for services			-					(32,500	)				-					-
Stock issued for services			-					18,269,800					-					18,305,000
Stock compensation expense			4,087,768					1,757,408					12,071,659					18,656,141
Deferred tax liability			-					(70,000	)				-					(70,000	)
Changes in Assets and Liabilities
Accounts receivable			986,755					(289,033	)				17,702					(816,756	)
Product deposit			708,392					276,623					613,209					(666,765	)
Inventory			(29,506	)				594,287					(409,823	)				(314,199	)
Other current assets			(103,835	)				22,702					(638,314	)				95,595
Deferred revenue			63,899					504,264					583,000					807,328
Accounts payable and accrued expenses			1,922,004					5,266,439					8,966,401					9,761,970
Net cash used in operating activities			(5,825,939	)				(6,394,232	)				(33,085,489	)				(12,131,614	)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for capitalized software costs			(1,401,186	)				(67,550	)				(3,132,693	)				(398,136	)
Purchase of equipment			(177,260	)				-					(247,365	)				-
Purchase of intangible assets			-					-					(22,231	)				-
Payment to seller for contingent consideration			-					-					-					(400,000	)
Net cash used in investing activities			(1,578,446	)				(67,550	)				(3,402,289	)				(798,136	)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash proceeds from private placement offering, net			-					14,900,220					13,495,270					14,900,220
Proceeds from issuance of debt instruments			-					-					15,000,000					-
Cash proceeds from Series A Preferred and Common Stock Offering			55,342,927					-					55,342,927					-
Cash proceeds from Series B Convertible Preferred Stock			-					-					-					2,892,500
Proceeds from convertible notes payable			-					-					-					2,350,000
Repayment of debt instruments			(15,000,000	)				-					(15,000,000	)				-
Cash proceeds from sale of common stock			-					-					-					2,338,349
Cash proceeds from sale of common stock under ATM			-					-					493,481					-
Cash proceeds from exercise of warrants			-					-					480,609					622,763
Cash proceeds from exercise of options			(150,000	)				2,000					670,750					302,400
Cash proceeds from sale of warrants			-					-					-					25,000
Payment of debt issuance costs			-					-					-					(15,000	)
Preferred stock dividends			(871,476	)				-					(871,476	)				-
Purchase of membership interest of WorkSimpli			-					-					(300,000	)				-
Distributions to non-controlling interest			(36,000	)				(36,000	)				(144,000	)				(157,223	)
Proceeds from notes payable			-					-					963,965					242,000
Repayment of notes payable			-					-					(1,494,784	)				(2,498,808	)
Net cash provided by financing activities			39,285,451					14,866,220					68,636,742					21,002,201
Net increase in cash			31,881,066					8,404,438					32,148,964					8,072,451
Cash at beginning of period			9,446,973					916,637					9,179,075					1,106,624
Cash at end of period		$	41,328,039				$	9,321,075				$	41,328,039				$	9,179,075
Cash paid for interest
Cash paid during the period for interest		$	314,986				$	1,072,210				$	435,048				$	1,665,171
Non-cash investing and financing activities:
Cashless exercise of options		$	-				$	-				$	8,730				$	-
Cashless exercise of warrants		$	-				$	-				$	-				$	49,551
Principal of Paycheck Protection Program loans forgiven		$	-				$	-				$	184,914				$	-
Additional purchase of membership interest in WorkSimpli issued in performance options		$	-				$	-				$	144,002				$	-
Deemed dividend from warrant price adjustments		$	-				$	73,636				$	-				$	1,289,657
Deemed distribution from warrants issued with Series B Convertible Preferred Stock		$	-				$	-				$	-				$	3,500,000
Stock yet to be issued for capitalized costs		$	-				$	-				$	-				$	40,000
Deemed distribution from down-round provision on unissued shares		$	-				$	-				$	-				$	194,022
Liability to issue common stock		$	-				$	-				$	-				$	76,348
Debt issuance costs for liability to issue shares		$	-				$	-				$	-				$	219,450
Conversion of convertible notes payable and interest for Series B Convertible Preferred Stock		$	-				$	-				$	-				$	607,500
Stock issued for capitalized costs		$	-				$	-				$	-				$	12,675
Warrants issued for debt instruments		$	-				$	-				$	6,270,710				$	-
Common stock issued for conversion of debt		$	-				$	1,119,408				$	-				$	1,119,408
Debt exchange agreement		$	-				$	25,000				$	-				$	25,000
Right of use asset		$	1,752,448				$	274,437				$	1,752,448				$	274,437
Right of use lease liability		$	1,786,034				$	285,323				$	1,786,034				$	285,323

About the Use of Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with GAAP, we use Adjusted EBITDA and Adjusted EPS as non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.

Adjusted EBITDA is defined as loss attributable to common shareholders before interest, taxes, depreciation and amortization, financing transaction expense, acceleration/amortization of debt discount, debt extinguishment, inventory valuation/deposit write-off, litigation costs, preferred stock dividends and stock-based compensation expense. We have provided below a reconciliation of Adjusted EBITDA to Net loss attributable to common shareholders, its most directly comparable GAAP financial measure.

Adjusted EPS is defined as the diluted net loss attributable to LifeMD, Inc common shareholders before stock-based compensation expense, acceleration/amortization of debt discount, debt extinguishment, depreciation and amortization expense, preferred stock dividends financing transaction expense and taxes. We have provided below a reconciliation of Adjusted EPS to Diluted loss per share attributable to LifeMD, Inc common shareholders.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms Adjusted EBITDA and Adjusted EPS may vary from that of others in our industry. Adjusted EBITDA and Adjusted EPS should not be considered as an alternative to net loss before taxes, net loss, loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.

Reconciliation of GAAP Net Loss to Adjusted EBITDA
(in whole numbers, unaudited)
		Fourth Quarter ended December 31,								Year ended December 31,
			2021				2020				2021				2020
Net loss attributable to common shareholders		$	(18,982,722	)		$	(32,250,729	)		$	(61,769,180	)		$	(63,362,964	)
Interest expense (excluding debt discount and acceleration of debt)			38,882				239,841				474,480				1,552,851
Depreciation & amortization expense			347,509				110,055				868,757				397,765
Amortization of debt discount			-				-				2,090,236				817,118
Loss on debt extinguishment, net			4,180,473				-				3,995,559				-
Warrant settlement			-				914,862				-				914,862
Financing transactions expense			543,398				175,000				1,802,469				237,012
Acceleration of debt discount			-				-				-				500,145
Inventory valuation/deposit adjustment			571,338				1,341,929				571,338				2,111,307
Litigation costs			-				-				279,666				-
Accrued interest on Series B Convertible Preferred Stock			114,685				114,685				455,000				114,685
Deemed distribution to holders of Series B Preferred stock			-				-				-				4,716,021
Preferred dividends			871,476				-				871,476				-
Stock-based compensation expense			4,087,768				20,027,208				12,071,659				36,961,141
Income tax provision			7,700				122,500				7,700				122,500
Adjusted EBITDA		$	(8,219,493	)		$	(9,204,649	)		$	(38,280,840	)		$	(14,917,557	)

Reconciliation of GAAP Diluted Loss per Share Attributable to Common Shareholders to Adjusted EPS
			Fourth Quarter ended December 31,								Year ended December 31,
				2021				2020				2021				2020
Diluted loss per share attributable to LifeMD, Inc. common shareholders			$	(0.62	)		$	(2.56	)		$	(2.29	)		$	(4.44	)
Adjustments to Reconcile GAAP Diluted Loss Per Share to Adjusted EPS
Stock-based compensation expense				0.13				1.59				0.45				2.59
Financing transaction expense				0.02				0.01				0.07				0.01
Depreciation & amortization expense				0.01				0.01				0.03				0.03
Loss on debt extinguishment, net				0.14				-				0.15				-
Preferred dividends				0.03				-				0.03				-
Amortization of debt discount				-				-				0.08				0.06
Income tax provision				0.00				0.01				0.00				0.01
Adjusted EPS			$	(0.29	)		$	(0.94	)		$	(1.48	)		$	(1.74	)

FAQ

What were LifeMD's revenue figures for FY2021?

LifeMD reported consolidated revenue of $92.9 million for FY2021, up 149% from the previous year.

What is the fourth quarter revenue for LifeMD in 2021?

LifeMD's fourth quarter revenue was $27.4 million, marking a 113% year-over-year increase.

What is LifeMD's revenue guidance for FY2022?

LifeMD expects revenue for FY2022 to be between $142 million and $148 million.

How much cash did LifeMD have at the end of FY2021?

As of December 31, 2021, LifeMD had over $41 million in cash with no debt.

When does LifeMD expect to achieve Adjusted EBITDA profitability?

LifeMD is on track to achieve Adjusted EBITDA profitability by the fourth quarter of 2022.